US45828J1034
© PR Newswire
11.12.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
News Preview
Poster PS5-08-16 Reports Early Observations from the INVINCIBLE-4 Study, an Ongoing Randomized, Presurgical Phase 2 Clinical Trial for Triple Negative Breast Cancer continue to show favorable safety 50% fewer grade 3 or higher Adverse Events were observed in the INT230-6 cohort compared to the Standard of Care ("SOC") neoadjuvant chemotherapy alon...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
News Preview
SHELTON, Conn., Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
News Preview
SHELTON, Conn., Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and incr...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
06.11.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
The Company expects to file a protocol amendment in the INVINCIBLE-4 Study to revise the dosing regimen for the INT230-6 treatment cohort, and to reinitiate patient enrollment in the first quarter of 2026
IT-01 Study manuscript publish...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
31.10.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
News Preview
SHELTON, Conn., Oct. 31, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognit...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
News Preview
The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety
The manuscript is open access...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
News Preview
A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed by the standard of care immunochemotherapy ("SOC")Safety looks favorable in Cohort ASome INT230-6 patients begin to show localized skin irritation, and new patient enro...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
SHELTON, Conn., Sept. 2, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprieta...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
News Preview
SHELTON, Conn., Aug. 12, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprieta...
Themefolio
Profiler
Peergroup
© PR Newswire
07.08.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Over $11 million raised since the beginning of 2Q 2025Cash runway extended into the second half of 2026In the INVINCIBLE-4 Study, patients receiving INT230-6 prior to the start of standard of care achieved high levels of tumor necrosis in 8 daysINT230-6 achieved 100% complete response rate in preclinical models of malignant peripheral nerve sheat...
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
News Preview
SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, a...
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. Announces Pricing of Public Offering
News Preview
SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, t...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
11.06.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
News Preview
SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, t...
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study
News Preview
SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, a...
Themefolio
Profiler
Peergroup
© PR Newswire
29.05.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
News Preview
SHELTON, Conn., May 29, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, an...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon
News Preview
SHELTON, Conn., May 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral investigational cancer therapies designed to kill tumors and increase immune system recognitio...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been treatedEuropean Medicines Agency Authorization to initiate INVINCIBLE-4-Study in FranceSHELTON, Conn., May 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focuse...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Canc
News Preview
INVINCIBLE-4 (SAKK/66/22) Study continues to recruit patients in eight sites in Switzerland
SHELTON, Conn. and BERN, Switzerland, May 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
News Preview
SHELTON, Conn., April 25, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers,...
Themefolio
Profiler
Peergroup
© PR Newswire
13.03.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
News Preview
32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screenedEight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screenedFinal sarcoma data from our first metastatic study and our INVINCIBLE-3 Study design was presented at the annual Connective Tissue Oncology Society Meeting...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2025
INTS
LISTED
NASDAQ
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
News Preview
INVINCIBLE-3 Study continues to recruit patients with leiomyosarcoma, liposarcoma and undifferentiated pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S., Canada, Europe and Australia
SHELTON, Conn., Jan. 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company")...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2024
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cance
News Preview
Enrollment is ongoing and seven sites in Switzerland have been activated
SHELTON, Conn. and BERN, Switzerland, Dec. 12, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumora...
Themefolio
Profiler
Peergroup
© PR Newswire
21.11.2024
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
News Preview
SHELTON, Conn., Nov. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, t...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2024
INTS
LISTED
NASDAQ
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS
News Preview
Phase 1/2 data showed a median overall survival ("mOS") of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone
INVINCIBLE-3 Study is recruiting and expected to enroll 333 patients with leiomyosarcoma, liposarcoma and undeferential pleomorphic sa...
Themefolio
Profiler
Peergroup
© PR Newswire
13.11.2024
INTS
LISTED
NASDAQ
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
News Preview
First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer
SHELTON, Conn., Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2024
INTS
LISTED
NASDAQ
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
News Preview
SHELTON, Conn., Nov. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recogn...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
INTS
LISTED
NASDAQ
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
News Preview
Testing the efficacy and safety of Intensity's lead drug candidate, INT230-6, when combined with Standard-of-Care versus Standard-of-Care alone
The endpoint is the change in pathological complete response rates
SHELTON, Conn. and BERN, Switzerland, Oct. 31, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq:...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
INTS
LISTED
NASDAQ
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
News Preview
SHELTON, Conn., Sept. 4, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender,...
Themefolio
Profiler
Peergroup
© PR Newswire
08.08.2024
INTS
LISTED
NASDAQ
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
News Preview
First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcomaCollaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 randomized, study in early-stage breast cancer in EuropeCash and investments of $6.3 million expected to fund operations into the first quarter of 202...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
